Free Access: Please Log In
This content is completely free—but you need to be logged in to read the full article. If you already have an account, please log in below. Otherwise, register for free to unlock instant access.
References (6)
- Volkow ND. The epidemic of fentanyl misuse and overdoses: challenges and strategies. World Psychiatry. 2021;20(2):195–196. PubMed CrossRef
- Jegede O, Parida S, De Aquino JP. Buprenorphine treatment of fentanyl-related opioid use disorder. Prim Care Companion CNS Disord. 2022;24(3):21cr03163. PubMed CrossRef
- Wakeman SE, Chang Y, Regan S, et al. Impact of fentanyl use on buprenorphine treatment retention and opioid abstinence. J Addict Med. 2019;13(4):253–257. PubMed CrossRef
- Godersky ME, Saxon AJ, Merrill JO, et al. Provider and patient perspectives on barriers to buprenorphine adherence and the acceptability of video directly observed therapy to enhance adherence. Addict Sci Clin Pract. 2019;14(1):11. PubMed CrossRef
- Silverstein SM, Daniulaityte R, Martins SS, et al. “Everything is not right anymore”: buprenorphine experiences in an era of illicit fentanyl. Int J Drug Policy. 2019;74:76–83. PubMed CrossRef
- Ahmed S, Bhivandkar S, Lonergan BB, et al. Microinduction of buprenorphine/naloxone: a review of the literature. Am J Addict. 2021;30(4):305–315. PubMed CrossRef
Buy PDF for $40
Please sign in or purchase this PDF for $40.
Save
Share
Cite
